Talfinium Investments

Talfinium Investments was a UK-based biotechnology company focused on the discovery and development of small molecule inhibitors of Complement Factor D. Founded by Dr. David Grainger and backed by the venture capital firm Medicxi, the company operated under an asset-centric model to advance next-generation therapies for rare complement-mediated disorders. In May 2018, Talfinium was acquired by Achillion Pharmaceuticals to expand its portfolio of Factor D inhibitors, which target the alternative pathway of the complement system. Following the subsequent acquisition of Achillion by Alexion Pharmaceuticals, these assets became part of AstraZeneca's rare disease pipeline, contributing to the development of treatments for conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy (C3G).